Fly With Jet Center Network
Where Jet Setter's Stay and Play
Learn to Fly Schools
cropper
  • HOME
  • Categories
    • Restaurants
    • Jets Charter Private
    • Fitness
    • Flight Training Centers
    • Jet Centers & FBO
    • Aircraft & Automobiles
    • Outdoor Fun
    • Hotels & Resorts
    • Extra Travel News
    • Featured
    • Catering
    • Restaurants Vegan
    • Toys For Boys
    • OJC Airport - Corporate Gold Directory
    • Business Directory Johnson County
    • Airport Sponsers
    • EAA
    • Ultralights
    • FXE Fort Lauderdale Business Directory
    • EAA AirVenture
September 04.2026
2 Minutes Read

Is Daily Aspirin for Heart Attack Prevention Still Valid? Experts Weigh In!

Casual indoor scene with newspaper and coffee mug.

Why the Aspirin Ritual Is Questioned

For many Americans, taking a low-dose aspirin each morning has been a staple of health routines aimed at preventing heart disease. However, recent shifts in medical guidelines are raising eyebrows and questions about the very efficacy of this practice. As the 63-year-old Margaret Hollis from Ohio reflects on her long-standing ritual of daily aspirin intake, health experts advise that it may not be the best preventive measure for everyone.

The context around aspirin's use has dramatically changed. While once hailed as a miracle drug capable of significantly reducing the chances of heart attacks, evidence now suggests that for many, particularly those over 60, the potential risks could outweigh the benefits.

The Change in Medical Guidance

Historically, aspirin's role in primary prevention—preventing a first heart attack or stroke—was widely accepted and encouraged by healthcare professionals. The American Heart Association and other bodies had previously recommended daily low-dose aspirin for many at elevated cardiovascular risk. This stance began to shift notably with a 2022 statement from the U.S. Preventive Services Task Force, which reversed previous guidelines by advising against initiating aspirin for primary cardiovascular prevention in adults age 60 and older.

It's not just Margaret Hollis who feels confused. Millions of Americans, around 29 million over 40, continue to depend on this daily ritual. What's driving this persistence? Simple routines and long-standing doctor recommendations, which some patients are reluctant to challenge.

Understanding Aspirin's Mechanism and Risks

Aspirin works as an anti-platelet agent, inhibiting an enzyme that promotes blood clotting, theoretically reducing the risk of blockages leading to heart attacks and strokes. However, these benefits must now be carefully weighed against the severe risks of internal bleeding, particularly gastrointestinal bleeding, which can occur even at low doses.

According to Dr. Faheem Ahmad from Franciscan Health, this risk especially escalates with age, leading to recommendations that are increasingly nuanced. While those who have already suffered a heart attack or stroke are advised to continue aspirin therapy, the decision becomes more complex for those who have not.

Primary vs. Secondary Prevention: What's the Difference?

It's critical to distinguish between primary and secondary prevention. In secondary prevention—applicable for those with a history of heart issues—aspirin remains a vital tool. Conversely, its role in primary prevention is fraught with uncertainty. Many healthcare professionals now recommend discussing individual risks before deciding on aspirin therapy for primary prevention, especially for older adults.

Conclusion: The Road Ahead

As the medical community continues to refine its understanding of cardiovascular health, patients like Margaret Hollis find themselves at a crossroads. Should they follow years of ingrained advice or reevaluate their choices with the guidance of modern medicine? The critical takeaway is clear: Always consult your healthcare provider to assess whether daily aspirin use is right for you.

Jets Charter Private

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts

Why Scottie Scheffler is the Favorite at the 2026 Masters with $21 Million Prize Fund

Update Scottie Scheffler: The Chase for an Unprecedented Third Green Jacket As the 2026 Masters Tournament draws near, intrigue surrounds defending champion Scottie Scheffler, who seeks to make history by capturing a third consecutive title at Augusta National Golf Club. Scheduled to commence on April 9, the tournament not only offers intense competition but also sets a groundbreaking $21 million prize fund, representing a strategic move by Augusta that underscores the shifting economics of professional golf. The Record Payout: Implications for the Future of Golf Augusta National’s announcement of a $21 million total prize fund—up from last year’s $20 million—signals a continuing commitment to rewarding players generously. With a projected winner's share of $3.78 million, this edition marks the largest first-place payout in Masters history. This financial growth contrasts with other major tournaments, which have seen static or less favorable adjustments. For example, the U.S. Open reached $21.5 million in 2025, while the PGA Championship offered $19.4 million. Despite being the only major without a title sponsor, Augusta National’s approach of elevating payouts annually places it at the forefront of championship economics amidst rising competition from alternative leagues like LIV Golf. A Look at Recent Masters Trends The historical narrative surrounding the Masters tournament often highlights the significance of player form leading into the week. Since 2010, only twice has the world number one claimed the Green Jacket despite dominant regular seasons. This anomaly suggests that Augusta's uniquely challenging layout requires skill sets that can adapt under pressure. Past winners, including Scottie Scheffler, have demonstrated powerful performances leading up to their victories, emphasizing the importance of consistency and course familiarity. Scottie Scheffler's Strong Statistical Profile Entering the 2026 Masters, Scheffler’s statistical metrics position him as the favorite. Leading the PGA Tour in "strokes gained: approach-the-green" for the 2025-26 season underscores his precision—a crucial factor at Augusta, where approach shots often dictate success. This timing is essential; the ability to navigate the course’s demanding greens can separate contenders from the rest. Winning back-to-back titles already mirrors the feats of Tiger Woods in the early 2000s, making Scheffler's pursuit not just a personal challenge but a remarkable chapter in golf history. Key Competitors: Who Else to Watch? While Scheffler is a standout favorite, courses like Augusta are treacherous for even the best. Defending champion Rory McIlroy, now equipped with the pressure of expectations after claiming his first Green Jacket in 2025, looks to fend off challengers like Jon Rahm and Xander Schauffele, both of whom have shown consistent form. Each contender's ability to perform in high-pressure situations could redefine the trajectory of their golfing careers during this major. The Significance of the Masters in Today’s Golf Landscape As the Masters approaches, questions about its future prominence in the global golf landscape arise. With its distinguished history and evolving prize structure, the tournament not only captivates audiences but also invites scrutiny on how professional golf will adapt in a fractured competitive environment. As both veteran champions and rising stars prepare to tee off, their performances could significantly impact their careers while contributing to the timeless lore of the Masters. In the shadow of historic achievement, fans of golf are reminded of the significance of tradition and excellence at Augusta National. Whether or not Scheffler claims his third title, the impending excitement of the 2026 Masters is certain to be unforgettable.

Synthetic Identity Fraud Crisis: Are Current Prosecution Tools Enough?

Update Understanding the Growing Challenge of Synthetic Identity FraudSynthetic identity fraud is becoming a silent epidemic, significantly affecting individuals and businesses alike in 2026. Unlike traditional identity theft, where a criminal steals a real person’s identity, synthetic identity fraud involves blending real personal information, such as social security numbers, with fabricated details to create entirely new identities that can pass routine verification checks. This misleading sophistication has caused concerns for regulators and financial institutions, prompting a reevaluation of existing laws and defenses against these emerging threats.The Alarming Numbers: Financial Losses SoarIn 2023, the Federal Trade Commission (FTC) recorded more than $10 billion in consumer fraud losses, while the FBI reported around $12.5 billion in cybercrime-related losses, with synthetic identity fraud emerging as a key contributor. As AI tools have become more affordable and accessible, organizations must brace for continuous increases in these figures. The FTC's findings suggest older Americans are disproportionately affected and often lose more money per incident compared to younger individuals, who file complaints more frequently. This alarming trend highlights the pressing need for enhanced protective measures and regulatory reforms.How AI is Transforming Financial FraudArtificial intelligence is at the heart of this crisis, transforming both the landscape and execution of financial fraud. By lowering the skill barrier, AI enables individuals with no prior criminal experience to execute complex schemes like producing convincing fake documents or using deepfake technologies. As fraud networks leverage these tools, traditional compliance frameworks struggle to keep pace with sophisticated methods aimed at bypassing identity verification systems.Gaps in Existing Legal FrameworksOne of the central issues is that the legal instruments currently guiding the prosecution of fraud—such as the Computer Fraud and Abuse Act—were established long before the rise of AI-generated synthetic media. Existing regulations were designed to address traditional fraud tactics, failing to accommodate the complexities introduced by AI. Consequently, proving intent in AI-assisted fraud is a monumental challenge, as the criminal processes involved may not include direct human actions at every stage. This has led to a precarious accountability void that savvy defense teams have begun to exploit.Proactive Measures: Future Strategies Against FraudAddressing synthetic identity fraud requires a paradigm shift in how organizations approach compliance and fraud prevention. Businesses must adopt advanced identity verification techniques that analyze multiple data signals rather than relying on simple document checks. Enhancing real-time Anti-Money Laundering (AML) monitoring can also help identify unusual transaction patterns associated with these synthetic identities. Implementing a risk-based compliance framework allows organizations to scrutinize high-risk scenarios more deeply. By partnering with technology firms that specialize in AML solutions, businesses can better safeguard against these evolving threats.A Call for Action and Forward-Thinking StrategiesYour organization cannot afford to wait until fraud cases escalate. The time to act is now, leveraging advanced technologies and stratagems that align with the rapidly changing financial landscape. By adopting forward-thinking compliance solutions, your business can stay ahead of synthetic identity fraud, ensuring not only protection against financial losses but also fostering trust and safety for customers.

Landmark SELECT Trial Reveals 20% Cardiovascular Risk Reduction Potential with GLP-1 Drugs

Update Revolutionary Findings in Cardiovascular Health: The SELECT Trial With obesity affecting nearly 42 percent of American adults, the SELECT trial marks a transformative moment in both obesity treatment and cardiovascular health management. This multicenter and double-blind study, involving over 17,600 adults aged 45 and older, illustrated that weekly injections of semaglutide 2.4 mg result in a 20% reduction of major cardiovascular events, which include cardiovascular death, nonfatal heart attacks, and strokes. This groundbreaking finding provides new hope for millions at risk. Understanding the Significance of 20% Risk Reduction While a 20% relative risk reduction stands as a significant headline figure, the absolute differences in the trial tell a larger story. Over a median follow-up of 34.2 months, major adverse cardiovascular events were observed in 6.5% of participants taking semaglutide, compared to 8.0% in the placebo group. Even minimal weight loss in patients led to reduced cardiovascular event rates, indicating that the drug’s mechanism may extend beyond weight management, potentially involving anti-inflammatory pathways and plaque stabilization. Historical Context: How Treatment Paradigms Have Evolved The FDA’s approval of semaglutide, branded as Wegovy, and its labeling as a cardiovascular risk reducer is unprecedented for weight-loss medications. Traditionally categorized with limited therapeutic options, patients living with obesity now have access to a treatment avenue backed by strong clinical evidence. This shift represents a considerable change not only in treatment options but also in the clinical pathways that insurers may adopt, which could lead to broader medication access. Broader Implications for the Healthcare System The SELECT trial and the resulting FDA approval have immense implications for healthcare insurance policies. Historically, anti-obesity medications faced restrictions under Medicare, often limiting coverage. However, a cardiovascular indication opens new doors for reimbursement, suggesting that payers may justify funding for a medication that costs over $1,300 monthly, making it accessible to millions more people across the country. Current Responses in the Medical Community The American College of Cardiology (ACC) has responded to these findings by revising its clinical guidelines to advocate for the use of GLP-1 receptor agonists among patients experiencing both obesity and cardiovascular disease. This change signifies recognition that obesity and heart health cannot be treated as separate issues. Moving forward, physicians will likely be more motivated to incorporate GLP-1 medications into treatment plans for their patients with obesity-related complications. The Importance of Lifestyle Integration While GLP-1 drugs like semaglutide exhibit promising results, the importance of lifestyle changes cannot be overstated. Studies, such as those from Harvard’s T.H. Chan School of Public Health, reveal that combining GLP-1 therapy with healthy lifestyle habits can significantly reduce cardiovascular risks among individuals with type 2 diabetes. This dual approach highlights that modern medicine should not overlook foundational health habits — diet, exercise, and social connection — which can enhance drug effectiveness and improve overall well-being. Conclusion: The Future of Obesity Treatment The FINDINGS from the SELECT trial and subsequent endorsements from the medical community emphasize a pivotal moment for obesity treatment and cardiovascular health management. This advancement is not just about medications; it's about changing lives, providing doctors with more tools to combat epidemic levels of obesity, and reducing the significant cardiovascular risks that accompany it. As our understanding and treatment of obesity evolve, patients finally have the opportunity to thrive.

Chambers First Class Connections

Luxury lifestyle innovations focusing on Learn2Fly and high-end Jet Centers, fashion, automobiles, technology, and gourmet dining, great Hotels &Golfing Resorts..

CFCConnections LLC

913-963-6354

AVAILABLE FROM 7AM - 7PM

ABOUT US

"Your insider guide to the pinnacle of luxury innovation," providing educational and inspiring content that helps affluent individuals stay ahead of the curve in elite lifestyle innovations.

© 2026 Chambers First Class Connections All Rights Reserved. W 154th Terr, Olathe, KS 66062-3133 . Contact Us . Terms of Service . Privacy Policy

{"company":"Chambers First Class Connections","address":"16114 W 154th Terr, Olathe, KS 66062-3133","city":"Olathe","state":"KS","zip":"66062-3133","email":"rick@rickchambersmarketing.com","tos":"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","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*